Two Sigma Investments
NBIX icon

Two Sigma Investments’s Neurocrine Biosciences NBIX Stock Holding History

Two Sigma Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,200
Closed -$213K – 3377
2016
Q3 		$213K Buy
+4,200
New +$209K ﹤0.01% 2922

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Two Sigma Investments's NBIX Position: Q1 2026 in Review

Two Sigma Investments increased its Neurocrine Biosciences (NBIX) stake by 211% in Q1 2026, buying an estimated $275M and bringing the position to 3,060,570 shares worth $403M. The position accounts for 0.33% of the portfolio, ranked #52.

Two Sigma Investments first reported a position in NBIX in Q2 2013 and has held it in 37 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Two Sigma Investments held 3,060,570 shares of Neurocrine Biosciences worth $403M as of Q1 2026.
  • Two Sigma Investments bought 2,075,759 Neurocrine Biosciences shares in Q1 2026, an estimated $275M.
  • Neurocrine Biosciences made up 0.33% of Two Sigma Investments's portfolio in Q1 2026, its #52 holding.
  • Two Sigma Investments first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 37 quarters since.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.